. 2020 Feb 6;12(2):376. doi: 10.3390/cancers12020376

Table 4.

Univariate and multivariate Cox-regression analysis for PFS and OS among patients with metastatic BC.

Cox Regression Analysis	Progression-Free Survival (PFS)				Overall Survival (OS)
Cox Regression Analysis	Univariate		Multivariate		Univariate		Multivariate
Covariates	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Age (>59)	0.811 (0.512–1.283)	0.370			0.677 (0.409–1.120)	0.129
Performance status (0–1)	0.431 (0.133–1.402)	0.162			0.363 (0.112–1.178)	0.091
Recurrent disease	1.575 (0.944–2.626)	0.082			1.837 (1.013–3.331)	0.045 *	4.072 (1.970–8.418)	0.000 *
Molecular subtype of tumor
HR-positive	0.910 (0.522–1.587)	0.740			0.918 (0.504–1.675)	0.781
HER2-positive	1.607 (0.923–2.798)	0.094			1.794 (0.951–3.385)	0.071
Triple-negative	1.559 (0.796–3.054)	0.195			1.401 (0.688–2.850)	0.353
No of organs affected (>2)	1.453 (0.914–2.310)	0.115			2.084 (1.255–3.461)	0.005 *	3.456 (1.897–6.294)	0.000 *
Metastatic sites
Liver	1.613 (1.017–2.560)	0.042 *	1.816 (1.126–2.930)	0.014 *	2.002 (1.195–3.353)	0.008 *	1.999 (1.142–3.499)	0.015 *
Lung	0.995 (0.631–1.568)	0.982			0.825 (0.497–1.368)	0.455
Bones	1.287 (0.809–2.049)	0.287			1.513 (0.911–2.514)	0.110
Lymph nodes	0.825 (0.524–1.297)	0.404			0.688 (0.418–1.135)	0.143
CNS	0.872 (0.434–1.751)	0.700			0.901 (0.427–1.901)	0.785
Skin	0.841 (0.364–1.943)	0.685			0.716 (0.308–1.666)	0.439
Total CTCs	1.866 (1.100–3.168)	0.021 *			1.558 (0.880–2.758)	0.128
CD47^high CTCs	2.192 (1.079–4.452)	0.030 *			1.433 (0.680–3.018)	0.344
PD-L1^high CTCs	2.977 (1.058–8.375)	0.039 *			2.793 (0.986–7.914)	0.053
CD47^highand/orPD-L1^high CTCs	2.373 (1.203–4.682)	0.013 *	2.719 (1.302–5.677)	0.008 *	1.610 (0.792–3.272)	0.189	2.398 (1.071–5.371)	0.034 *

* Statistical significance at the p < 0.05 level.